SLITRK5: A Potential Drug Target and Biomarker (G26050)

Target Name: SLITRK5

NCBI ID: G26050

SLITRK5

SLITRK5: A Potential Drug Target and Biomarker

SLITRK5, also known as Leucine-rich repeat-containing protein 11, is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to study, and its potential as a drug or biomarker has significant implications for the development of new treatments.

SLITRK5 is a protein that is expressed in a variety of tissues, including the brain, muscle, heart, and testes. It is characterized by a unique structure that consists of a long N-terminus, a short alpha-helices region, and a long C-terminus. The protein has a total length of 180 amino acids and a calculated molecular mass of 19.9 kDa.

One of the most significant features of SLITRK5 is its ability to interact with various molecules, including small molecules, peptides, and proteins. This interaction has led to its potential as a drug target. The protein has been shown to interact with a variety of small molecules, including inhibitors of the protein kinase CKL3, which is a key regulator of cell growth and survival. Additionally, SLITRK5 has been shown to interact with antibodies that are capable of targeting it for diagnostic purposes, such as ELISP1 and ELISP2, which are monoclonal antibodies that are capable of recognizing specific epitopes on the protein.

In addition to its potential as a drug target, SLITRK5 has also been identified as a potential biomarker for several diseases. The protein has been shown to be expressed in a variety of tissues and has been used as a biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that SLITRK5 is expressed in the brains of patients with Alzheimer's disease, and that it is decreased in the brains of patients with Parkinson's disease. Additionally, SLITRK5 has been shown to be expressed in the blood vessels of patients with cardiovascular disease, and that it is decreased in the blood vessels of patients with hypertension.

The unique structure and function of SLITRK5 have also made it an attractive target for researchers studying the regulation of protein expression and turnover. Studies have shown that SLITRK5 is involved in the regulation of protein expression and turnover in various tissues, including the brain, muscle, and heart. For example, research has shown that SLITRK5 is involved in the regulation of the expression of the neurotransmitter receptor NGRIP, which is involved in pain perception and neurotransmission. Additionally, studies have shown that SLITRK5 is involved in the regulation of the expression of the protein involved in cell growth and survival, PDGF-BB.

In conclusion, SLITRK5 is a protein that has significant potential as a drug target and biomarker. Its unique structure and function have made it an attractive target for researchers to study, and its potential as a drug or biomarker has significant implications for the development of new treatments for a variety of diseases. Further research is needed to fully understand the role of SLITRK5 in various biological processes and to develop effective treatments based on its unique properties.

Protein Name: SLIT And NTRK Like Family Member 5

Functions: Suppresses neurite outgrowth

The "SLITRK5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLITRK5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets